Abstract: The present disclosure describes a number of anti-ROR1 antibodies. Disclosed herein are anti-ROR1 antibodies comprising certain complementarity determining regions (CDRs) as disclosed. The anti-ROR1 antibodies disclosed herein can be used to treat various diseases such as cancer.

Abstract: The present disclosure describes a number of anti-5T4 antibodies. In some embodiments, anti-5T4 antibodies comprising certain complementarity determining regions (CDRs) are disclosed. The anti-5T4 antibodies disclosed herein can be used to treat various diseases such as cancer.

Abstract: The present disclosure describes a number of anti-NKG2D antibodies. In some embodiments, anti-NKG2D antibodies comprising certain complementarity determining regions (CDRs) are disclosed. The anti-NKG2D antibodies disclosed herein can be used to treat various diseases such as cancer.

Abstract: Disclosed herein are precursor tri- specific antibody constructs comprising (i) a first binding domain that binds to a tumor associated antigen, (ii) a second binding domain that binds to a first natural killer (NK) cell surface antigen, and (iii) a third binding domain that binds to a T cell surface antigen or a second NK cell surface antigen. The antibody constructs further comprises regulatory domains that regulate binding to the T cell or NK cell surface antigen. Pharmaceutical compositions comprising the precursor constructs and their uses for treating tumors are also disclosed.

Abstract: Precursor tri-specific antibody constructs comprising at least one tumor associated antigen binding domain, a T-cell binding domain, and a regulatory domain having enhanced half-life, are described herein. Further, methods of producing the precursor tri-specific antibody constructs are disclosed. Pharmaceutical compositions comprising the precursor constructs and their uses for treating tumors are also disclosed.